Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19

Једноставна страница ставке
dc.citation.spage3117
dc.citation.volume11
dc.contributor.authorZlatković-Švenda, Mirjana
dc.contributor.authorOvuka, Milica
dc.contributor.authorOgrič, Manca
dc.contributor.authorČučnik, Saša
dc.contributor.authorŽigon, Polona
dc.contributor.authorRadivčev, Aleksandar
dc.contributor.authorZdravković, Marija
dc.contributor.authorRadunović, Goran
dc.date.accessioned2024-12-03T12:08:55Z
dc.date.available2024-12-03T12:08:55Z
dc.date.issued2023
dc.description.abstractAntiphospholipid antibodies (aPLA) are a laboratory criterion for the classification of antiphospholipid syndrome (APS) and are known to cause clinical symptoms such as vascular thrombosis or obstetric complications. It is suggested that aPLA may be associated with thromboembolism in severe COVID-19 cases. Therefore, we aimed to combine clinical data with laboratory findings of aPLA at four time points (admission, worsening, discharge, and 3-month follow-up) in patients hospitalized with COVID-19 pneumonia. In 111 patients with COVID-19 pneumonia, current and past history of thrombosis and pregnancy complications were recorded. Nine types of aPLA were determined at four time points: anticardiolipin (aCL), anti- 2-glycoprotein I (anti- 2GPI), and antiphosphatidylserine/ prothrombin (aPS/PT) of the IgM, IgG, or IgA isotypes. During hospitalization, seven patients died, three of them due to pulmonary artery thromboembolism (none were aPLA positive). Only one of the five who developed pulmonary artery thrombosis was aPLA positive. Out of 9/101 patients with a history of thrombosis, five had arterial thrombosis and none were aPLA positive at admission and follow-up; four had venous thrombosis, and one was aPLA positive at all time points (newly diagnosed APS). Of these 9/101 patients, 55.6% were transiently aPLA positive at discharge only, compared to 26.1% without a history of thrombosis (p = 0.041). Patients with severe forms of COVID-19 and positive aPLA should receive the same dose and anticoagulant medication regimen as those with negative aPLA because those antibodies are mostly transiently positive and not linked to thrombosis and fatal outcomes.
dc.identifier.doi10.3390/biomedicines11123117
dc.identifier.urihttps://vaseljena.ues.rs.ba/handle/123456789/1372
dc.language.isoen
dc.publisherMDPI
dc.sourceBiomedicines
dc.subjectCOVID-19; antiphospholipid syndrome; vascular thrombosis; antiphospholipid antibodies; anticardiolipin antibodies (aCL); anti- 2-glycoprotein I antibodies (anti- 2GPI); anti-phosphatidylserine-prothrombin (aPS/PT) antibodies
dc.titleAntiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19
dc.typeArticle
Датотеке
Оригинални завежљај
Сада се приказује 1 - 1 од 1
Сличица
Име:
Antiphospholipid Antibodies and Vascular Thrombosis in.pdf
Величина:
975.72 KB
Формат:
Adobe Portable Document Format
Опис:
Преузимање
Свежањ лиценце
Сада се приказује 1 - 1 од 1
Сличица
Име:
license.txt
Величина:
1.71 KB
Формат:
Item-specific license agreed to upon submission
Опис:
Преузимање
Колекције
Медицински факултет [Научни радови] / Faculty of Medicine [Scientific papers]